Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine

Belda, F. Javier; Mora, Oscar Yahevh Carrera; Martínez, Mónica López; Torres, Nerea; Vivanco, Ana; Christie, Rebecca; Crowley, Michael

doi:10.1016/j.vaccine.2022.04.006

Cited by 2 publications

(8 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously described [16], the pre-vaccination samples in the mRNA-1273 panel showed positive values for two participants suggesting that they had been previously infected with SARS-CoV-2 (participants 5 and 15). The post-vaccination samples collected from these participants after the first dose showed the largest antibody responses in the panel.…”

Section: Mrna-1273 (Moderna) Seroconversion Panelsupporting

confidence: 66%

“…Comparison of the CLIA and ELISA results for the mRNA-1273 panel showed good agreement between these assays. [16] In addition, neutralization assays were conducted in this study and showed congruence between the neutralization assay and the CLIA. Neutralizing activity that blocks viral entry into cell has been shown to be responsible for antibody-mediated prevention of coronavirus infection.…”

Section: Discussionmentioning

confidence: 66%

“…Comparison of the CLIA and ELISA results for the mRNA-1273 panel showed good agreement between these assays. [16]…”

Section: Discussionmentioning

confidence: 99%

“…As previously described [16], the mRNA-1273 panel was made up of undiluted, unpreserved serum samples collected from 15 participants between 22 December 2020 and 25 February 2021. The donors were health adults (21-76 years old) who received the prescribed course of mRNA-1273 vaccines (two injections of 100 µg -objective target 28 days apart).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration

Belda

Mora

López-Martı́nez

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Seroconversion panels were collected before and after vaccination with three COVID-19 vaccines: two mRNA vaccines (mRNA-1273 and BNT-162b2) and one adenovirus vector vaccine (Ad26.COV2.S). The panels were tested for antibody activity by chemiluminescent immunoassay, ELISA and one was tested in a pseudovirus neutralization assay. Participants positive for anti-SARS-CoV-2 antibodies before vaccination (18.6%) had a higher response to the first vaccine dose than participants who tested negative. For two-dose vaccines, older participants showed a lower response to the first dose than younger participants. All participants showed positive antibody responses after the second vaccine. For the adenovirus vector vaccine, two participants did not generate antibody responses two weeks and two months after vaccination. Three participants were negative at two weeks but positive at two months. Pseudovirus neutralization showed good correlation with antibody activity (correlation coefficient =0.78, p<0.0001). Antibody responses in participants over 45 years old tended to be less robust.

show abstract

Section: Mrna-1273 (Moderna) Seroconversion Panelsupporting

confidence: 66%

Section: Discussionmentioning

confidence: 66%

“…Comparison of the CLIA and ELISA results for the mRNA-1273 panel showed good agreement between these assays. [16]…”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration

Belda

Mora

López-Martı́nez

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…As previously described, 22 the mRNA-1273 panel was made up of undiluted, unpreserved serum samples collected from 15 participants between December 22, 2020, and February 25, 2021. The donors were healthy adults (21-76 years old) who received the prescribed course of mRNA-1273 vaccines (2 injections of 100 µg-objective target 28 days apart).…”

Section: Seroconversion Panel Collectionmentioning

confidence: 99%

Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration

Belda,

Mora,

Lopez-Martinez

et al. 2023

Clin Med�Insights�Blood�Disord

Self Cite

View full text Add to dashboard Cite

Vaccines are an important tool in combating the COVID-19 pandemic. Two mRNA vaccines (mRNA-1273 and BNT-162b2) and an adenovirus vector vaccine (Ad26.COV2.S) were among the first vaccines to be approved by global regulatory authorities. The aim of this observational study was to characterize the levels and time course of the generation of anti-SARS-CoV-2 spike protein antibodies after vaccination with 3 different vaccines and the neutralizing activity of these antibodies. Seroconversion panels were generated from blood samples collected before and after vaccination with 3 COVID-19 vaccines: mRNA-1273, BNT-162b2, and Ad26.COV2.S. The seroconversion panels were tested for antibody activity by chemiluminescent immunoassay or enzyme-linked immunosorbent assay (ELISA), and 1 panel was tested for neutralization activity in a pseudovirus assay. Participants positive for anti-SARS-CoV-2 antibodies before vaccination (18.6%) had a higher response to the first dose than participants who tested negative. For 2-dose vaccines, older participants showed a lower response to the first dose than younger participants. All participants showed positive responses after the second vaccine. For the adenovirus vector vaccine, 2 participants did not generate antibody responses after vaccination. Four participants were negative at 2 weeks but positive at 2 months. Pseudovirus neutralization showed good correlation with antibody activity (correlation coefficient = 0.78, P < .0001). Antibody responses in participants over 45 years old tended to be less robust. Participants that had been infected with SARS-CoV-2 and had antibodies prior to vaccination showed a more robust response to initial vaccination. Older participants (>45 years) showed less robust responses to both types of vaccine. All participants receiving full mRNA vaccination showed positive antibody responses. Some participants receiving the adenovirus vaccine did not respond. Antibody responses correlated well with neutralization activity. Seroconversion panels can be useful in the development of antibody assays and in investigating their effectiveness against new SARS-CoV-2 variants.

show abstract

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine

Cited by 2 publications

References 8 publications

Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration

Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration

Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration

Contact Info

Product

Resources

About